(EMAILWIRE.COM, November 14, 2018 ) Drug manufacturing companies are offering tranexamic acid for the treatment of acute gastrointestinal bleeding. Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma or surgery and is now finding applications for gastrointestinal diseases. Tranexamic acid reduces clot breakdown, thus reducing the duration and amount of bleeding. This reduces mortality rate (from 10% to 7.5%) and the probability of blood transfusion by about 30%. Major companies manufacturing tranexamic acid include Abbott Laboratories, Pfizer, GlaxoSmithKline and Bayer AG.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL GASTROINTESTINAL DRUGS MARKET TO GROW TO $67 BILLION BY 2021
North America was the largest region in the gastrointestinal drugs market in 2017, accounting for a little less than one-third of the global market share. This was mainly due to the high prevalence of obesity and digestive diseases due to unhealthy lifestyle in the North American countries. According to the National Center for Health Statistics, more than one-third (36.5%) of U.S adults were obese during 2011-2014.
Order the report at http://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market-report-2018
According to The Business Research Companys Consultant, Nitin Gianchandani, growing R&D activities for the development of new drugs in the treatment of gastrointestinal diseases is an emerging trend in the market. Some of the major gastrointestinal pipeline products include Perjeta (Roche), Keytruda (Merck), TAS-118 (Taiho Pharmaceutical), NeuVax (Galena Biopharma), Ipatasertib (Genentech), Durvalumab (AstraZeneca) and Napabucasin (Boston Biomedical). Technological advancements in the treatment of gastrointestinal diseases are expected to boost the market during the forecast period.
Download a sample of the report at http://www.thebusinessresearchcompany.com/sample.aspx?id=273&type=smp
Takeda Pharmaceuticals was the largest competitor in the gastrointestinal diseases drugs market in 2017, with revenues of $5.1 billion in 2015. As a part of its growth strategy, in 2014, the company launched ENTYVIO (vedolizumab), a gut-selective biologic for the treatment of ulcerative colitis and Crohns disease. Through specialized and strategic in-house development, external partnerships, in-licensing and acquisitions, Takeda also has a number of promising early-stage gastroenterology (GI) assets in development.
The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
Gastrointestinal Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company’s management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: http://in.linkedin.com/company/the-business-research-company
Marketing TBRC
+91 8897263534
Marketing@tbrc.info
Source: EmailWire.Com 
